Last reviewed · How we verify
Licensed RSV Vaccine
Stimulates the immune system to produce antibodies against RSV
Stimulates the immune system to produce antibodies against RSV Used for Respiratory Syncytial Virus (RSV) infection.
At a glance
| Generic name | Licensed RSV Vaccine |
|---|---|
| Also known as | AREXVY |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
This vaccine works by introducing a piece of the RSV virus to the body, which triggers an immune response and the production of antibodies to fight the virus.
Approved indications
- Respiratory Syncytial Virus (RSV) infection
Common side effects
Key clinical trials
- Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
- A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age (PHASE3)
- Systems Biological Analysis of Immune Responses to RSV Vaccine (PHASE4)
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older (PHASE1, PHASE2)
- Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) (PHASE4)
- A Study of IVX-A12 in Adults Participants (PHASE2)
- A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV). (PHASE2)
- A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed RSV Vaccine CI brief — competitive landscape report
- Licensed RSV Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI